These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 26036708)

  • 1. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for anti-VEGF treatment of diabetic macular edema.
    Bandello F; Berchicci L; La Spina C; Battaglia Parodi M; Iacono P
    Ophthalmic Res; 2012; 48 Suppl 1():16-20. PubMed ID: 22907145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetic macular edema.
    Lang GE
    Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues.
    Stewart MW
    Curr Diabetes Rev; 2012 Jul; 8(4):237-46. PubMed ID: 22515701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy for diabetic macular edema.
    Al Rashaed S; Arevalo JF
    Middle East Afr J Ophthalmol; 2013; 20(4):315-20. PubMed ID: 24339681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for diabetic macular edema.
    Schwartz SG; Flynn HW; Scott IU
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):397-405. PubMed ID: 25141904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological approach to diabetic macular edema.
    Bandello F; Casalino G; Loewenstein A; Goldstein M; Pelayes D; Battaglia Parodi M
    Ophthalmic Res; 2014; 51(2):88-95. PubMed ID: 24356667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor and diabetic macular edema.
    Lally DR; Shah CP; Heier JS
    Surv Ophthalmol; 2016; 61(6):759-768. PubMed ID: 27045225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG
    Arch Intern Med; 2012 Jul; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetic Macular Edema: Traditional and Novel Treatment.
    Tomić M; Vrabec R; Poljičanin T; Ljubić S; Duvnjak L
    Acta Clin Croat; 2017 Mar; 56(1):124-132. PubMed ID: 29120156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular endothelial growth factor in diabetic retinopathy.
    Iacono P; Battaglia Parodi M; Bandello F
    Dev Ophthalmol; 2010; 46():39-53. PubMed ID: 20703031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on nonsurgical therapy for diabetic macular edema.
    Witkin AJ; Brown GC
    Curr Opin Ophthalmol; 2011 May; 22(3):185-9. PubMed ID: 21427573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary.
    Giuliari GP; Guel DA; Cortez MA; Cortez RT
    Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.
    Domalpally A; Ip MS; Ehrlich JS
    Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
    Kakkassery V; Winterhalter S; Joussen AM
    Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.